Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive tumor of the central nervous system. Since these tumors are highly invasive and refractory to conventional treatment, most patients diagnosed with GBM present an average survival of 14.6 months. Therefore, the development of more effective treatments against GBM is essential and it will bring benefit to a myriad of patients. …